CR11457A - Composiciones farmaceuticas que contienen antagonistas de bradykinin y acido hialuronico y los usos de los mismos - Google Patents

Composiciones farmaceuticas que contienen antagonistas de bradykinin y acido hialuronico y los usos de los mismos

Info

Publication number
CR11457A
CR11457A CR11457A CR11457A CR11457A CR 11457 A CR11457 A CR 11457A CR 11457 A CR11457 A CR 11457A CR 11457 A CR11457 A CR 11457A CR 11457 A CR11457 A CR 11457A
Authority
CR
Costa Rica
Prior art keywords
pharmaceutical compositions
compositions containing
same
bradykinin antagonists
hialuronic acid
Prior art date
Application number
CR11457A
Other languages
English (en)
Inventor
Alberto Maggi Carlos
Giuliani Sandro
Quartara Laura
Original Assignee
Luso Farmaco Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luso Farmaco Inst filed Critical Luso Farmaco Inst
Publication of CR11457A publication Critical patent/CR11457A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Se describen las composiciones farmaceuticas que contienen, como ingredientes activos, una mezcla de un polimero de acýdo hialuronico con un antagonista del receptor de bradiquia B2.
CR11457A 2007-11-23 2010-05-21 Composiciones farmaceuticas que contienen antagonistas de bradykinin y acido hialuronico y los usos de los mismos CR11457A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002225A ITMI20072225A1 (it) 2007-11-23 2007-11-23 "composizioni farmaceutiche a base di antagonisti della bradichinina ed acido ialuronico e loro uso"

Publications (1)

Publication Number Publication Date
CR11457A true CR11457A (es) 2010-11-05

Family

ID=40314753

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11457A CR11457A (es) 2007-11-23 2010-05-21 Composiciones farmaceuticas que contienen antagonistas de bradykinin y acido hialuronico y los usos de los mismos

Country Status (40)

Country Link
US (1) US9101627B2 (es)
EP (1) EP2222275B1 (es)
JP (1) JP5383695B2 (es)
KR (1) KR101585868B1 (es)
CN (1) CN101868225B (es)
AP (1) AP2628A (es)
AR (1) AR069407A1 (es)
AT (1) ATE529096T1 (es)
AU (1) AU2008328311B2 (es)
BR (1) BRPI0820402A2 (es)
CA (1) CA2706398C (es)
CL (1) CL2008003475A1 (es)
CO (1) CO6270301A2 (es)
CR (1) CR11457A (es)
CY (1) CY1112134T1 (es)
DK (1) DK2222275T3 (es)
EA (1) EA017626B1 (es)
EC (1) ECSP10010153A (es)
ES (1) ES2374861T3 (es)
GE (1) GEP20125602B (es)
HN (1) HN2010001037A (es)
HR (1) HRP20110904T1 (es)
IL (1) IL205860A (es)
IT (1) ITMI20072225A1 (es)
MA (1) MA31913B1 (es)
MX (1) MX2010005484A (es)
MY (1) MY148685A (es)
NI (1) NI201000087A (es)
NZ (1) NZ585514A (es)
PA (1) PA8804801A1 (es)
PE (1) PE20091422A1 (es)
PL (1) PL2222275T3 (es)
PT (1) PT2222275E (es)
RS (1) RS52045B (es)
SI (1) SI2222275T1 (es)
TN (1) TN2010000215A1 (es)
TW (1) TWI448292B (es)
UA (1) UA97867C2 (es)
WO (1) WO2009065507A2 (es)
ZA (1) ZA201003586B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL420378A1 (pl) * 2014-05-30 2017-10-23 Nataliia Mykolaivna Derkach Stabilizowany roztwór na bazie substancji czynnych, sposób otrzymywania stabilizowanego roztworu substancji czynnych, kompozycja farmaceutyczna na bazie stabilizowanego roztworu substancji czynnych (dwa warianty)
CN107106594A (zh) * 2014-12-26 2017-08-29 生化学工业株式会社 改善眼的自觉症状的制剂和方法
WO2020022791A1 (ko) 2018-07-25 2020-01-30 (주)알테오젠 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물
CN112203642B (zh) 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
CN121472194A (zh) 2020-01-23 2026-02-06 阿特根公司 具有改善的稳定性的新玻尿酸酶变体及含有其的药物组合物
US11401303B2 (en) * 2020-06-15 2022-08-02 Taian City Qihang Biotechnology Co. Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof
JP7622088B2 (ja) 2020-08-07 2025-01-27 アルテオジェン・インコーポレイテッド 組換えヒアルロニダーゼの生産方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635489B2 (en) * 2001-05-18 2009-12-22 Leneau Holdings, Llc Ingestion of hyaluronic acid for improved joint health
ITMI20021247A1 (it) 2002-06-07 2003-12-09 Menarini Ricerche Spa Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche
ITMI20041963A1 (it) * 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"

Also Published As

Publication number Publication date
EA017626B1 (ru) 2013-01-30
HN2010001037A (es) 2012-12-10
PL2222275T3 (pl) 2012-03-30
KR20100096106A (ko) 2010-09-01
IL205860A (en) 2013-01-31
GEP20125602B (en) 2012-08-10
CY1112134T1 (el) 2015-11-04
CN101868225B (zh) 2013-06-12
PE20091422A1 (es) 2009-10-17
TWI448292B (zh) 2014-08-11
DK2222275T3 (da) 2012-01-02
ATE529096T1 (de) 2011-11-15
MA31913B1 (fr) 2010-12-01
MX2010005484A (es) 2010-06-07
ECSP10010153A (es) 2010-06-29
CA2706398C (en) 2016-07-05
JP5383695B2 (ja) 2014-01-08
IL205860A0 (en) 2010-11-30
PA8804801A1 (es) 2009-06-23
WO2009065507A3 (en) 2009-09-03
CO6270301A2 (es) 2011-04-20
NZ585514A (en) 2012-01-12
TN2010000215A1 (en) 2011-11-11
SI2222275T1 (sl) 2012-01-31
PT2222275E (pt) 2012-01-16
NI201000087A (es) 2011-07-18
AP2010005265A0 (en) 2010-06-30
RS52045B (sr) 2012-04-30
WO2009065507A2 (en) 2009-05-28
CA2706398A1 (en) 2009-05-28
AU2008328311B2 (en) 2013-02-28
AU2008328311A1 (en) 2009-05-28
TW200927151A (en) 2009-07-01
BRPI0820402A2 (pt) 2015-05-19
ES2374861T3 (es) 2012-02-22
MY148685A (en) 2013-05-31
CN101868225A (zh) 2010-10-20
AP2628A (en) 2013-03-26
ITMI20072225A1 (it) 2009-05-24
US20100292156A1 (en) 2010-11-18
AR069407A1 (es) 2010-01-20
US9101627B2 (en) 2015-08-11
KR101585868B1 (ko) 2016-01-22
UA97867C2 (ru) 2012-03-26
HRP20110904T1 (hr) 2011-12-31
ZA201003586B (en) 2011-08-31
JP2011504473A (ja) 2011-02-10
HK1149714A1 (en) 2011-10-14
CL2008003475A1 (es) 2009-03-27
EP2222275A2 (en) 2010-09-01
EA201000678A1 (ru) 2010-12-30
EP2222275B1 (en) 2011-10-19

Similar Documents

Publication Publication Date Title
UY32036A (es) Derivados de ciclohexil-amida, composiciones farmacéuticas que los contienen, su preparación y aplicaciones
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
UY31124A1 (es) Derivados de oxiadazol y su uso como potenciadores del receptor metabotropico de glutamato - 842
CO6460772A2 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
ECSP12012042A (es) Derivados de pirazol como inhibidores de jak
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
PE20151437A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
BR112015018087A8 (pt) composto, composição farmacêutica e uso
CR20110599A (es) Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos
NI202000028A (es) Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR20170590A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
UY32029A (es) "derivados de pirazolo -[5.1-b] - oxazol, su prepraración, composiciones farmacéuticas que los contienen y aplicaciones"
MX2019011545A (es) Composiciones celulares y de andamio inyectables.
PA8804801A1 (es) Composiciones farmaceuticas que contienen antagonistas de bradiquinina y acido hialuronico y sus usos
CO6321246A2 (es) Compuestos novedosos activos como antagonistas de receptor muscarinico
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
MX375183B (es) Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.
CL2012001759A1 (es) Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica.
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
UY32410A (es) Azetidinas como antagonistas del receptor de histamina3
CR20110021A (es) Composiciones farmaceuticas basadas en antagonistas del receptor de quinina b2 y corticosteroides, y su uso
UA102010C2 (ru) Комбинация активных ингредиентов, которая содержит нестероидное противовоспалительное лекарственное средство и производное колхикозида